# RMC-6236

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/rmc-6236
Canonical HTML page: https://getyourbrief.com/entity/rmc-6236

## Timeline

- **2026-08-10**: Lead Plaintiff Deadline — Deadline for investors to move for appointment as lead plaintiff in the securities class action.
- **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
- **2026-06-15**: Securities Class Action Announced — Hagens Berman announces the filing of a federal securities class action lawsuit and begins soliciting investor clients.
- **2026-04-26**: Stock Crash and Corrective Disclosure — Erasca shares plunge 48% on news that Revolution Medicines accused the company of patent infringement and that a trial patient died a month after receiving ERAS-0015. Class period ends.
- **2026-03-12**: Alleged Misleading Statements — Erasca reportedly assured investors of ERAS-0015's IP protection and made dose-equivalence comparisons to RevMed's RMC-6236.
- **2025-12**: Axsome full-year 2025 results — Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
- **2025-06**: Revolution Medicines mid-2025 data readout — RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
- **2025-01-14**: Class Period Begins — Start of the period during which Erasca allegedly made misleading statements that inflated its stock price.

## Recent coverage (5 stories, network-wide)

### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1
2026-07-07 06:57:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis

### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
2026-07-07 06:57:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome

### Erasca Hit With Securities Class Action After $2.8B Market Cap Loss
2026-06-16 14:03:48 · Sector: legal · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2

A securities fraud lawsuit alleges Erasca misled investors about IP and drug safety, triggering a 48% stock drop. Investors have until August 10, 2026 to seek lead plaintiff status.
Full story: https://getlegalbrief.com/story/erasca-securities-class-action-2-8b-loss

### Patient Death in Erasca Trial Sparks Securities Fraud Suit at $2.8B Cost
2026-06-16 14:03:41 · Sector: health · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2

Following a patient death in its ERAS-0015 trial, Erasca faces allegations it withheld risks, leading to a 48% stock collapse. The case underscores threats to clinical transparency.
Full story: https://gethealthbrief.com/story/erasca-patient-death-2-8b-securities-suit

### Erasca's Pan-RAS Drug ERAS-0015 Hit by IP War, Patient Death, $2.8B Loss
2026-06-16 14:03:32 · Sector: bio · Sentiment: Very Bearish · Impact: 7/10 · Sources: 2

Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Full story: https://getbiobrief.com/story/erasca-eras-0015-ip-death-2-8b-lawsuit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.